Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
-
Published:2023-03-10
Issue:6
Volume:12
Page:2155
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Rodolakis Ioannis1, Pergialiotis Vasilios1ORCID, Liontos Michalis2ORCID, Haidopoulos Dimitrios1, Loutradis Dimitrios1, Rodolakis Alexandros1, Bamias Aristotelis2ORCID, Thomakos Nikolaos1
Affiliation:
1. Division of Gynecologic Oncology, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 10679 Athens, Greece 2. Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Abstract
The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlier seems to be important, its accuracy in determining patients with a shorter overall survival remains arbitrary. Moreover, standardization of the actual scoring system that was initially developed as a 6-tiered score and adopted as a 3-tiered score is still needed, as several studies suggest that a 2-tiered system is preferable. Given its actual importance in detecting patients with shorter progression-free survival, research should also focus on the actual predictive value of determining patients with platinum resistance, as a suboptimal patient response to standard neoadjuvant chemotherapy might help determine patients at risk of an earlier recurrence. In the present review, we summarize current knowledge retrieved from studies addressing outcomes related to the chemotherapy response score in epithelial ovarian cancer patients undergoing neoadjuvant chemotherapy and discuss differences in outcome reporting to help provide directions for further research.
Reference25 articles.
1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer. 2. Cancer Statistics in China, 2015;Chen;CA Cancer J. Clin.,2016 3. Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis;Sehouli;Int. J. Gynecol. Cancer,2010 4. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial;Katsumata;Lancet Oncol.,2013 5. Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer;Nishio;Jpn. J. Clin. Oncol.,2020
|
|